SCHEMBL9921869

SCHEMBL9921869

c1cc(-c2ccc(-c3ccc(-c4ccc(-n5c6ccccc6c6cnccc65)cc4)cn3)nc2)cc(-n2c3ccccc3c3cnccc32)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAOA P21397 4/20 0.39
MAOB P27338 4/20 0.39
ACHE P22303 1/20 0.39
GRM5 P41594 3/20 0.35
HSD17B1 P14061 1/20 0.35
HSD17B2 P37059 1/20 0.35
CYP2D6 P10635 1/20 0.34
CDK4 P11802 1/20 0.34
CDK6 Q00534 1/20 0.34
MAPK10 P53779 1/20 0.34
MAPT P10636 3/20 0.33
MEN1 O00255 1/20 0.33
HSP90AA1 P07900 1/20 0.33
KMT2A Q03164 1/20 0.33
CYP1A2 P05177 1/20 0.32
METAP2 P50579 1/20 0.32
HDAC4 P56524 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12919277 0.97 CDK4 (0.39) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL969757 0.96 MAOA (0.41) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL12919319 0.94 MAOA (0.38) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL16016345 0.93 KDM4E (0.39) KDM4EATML3MBTL1GRM5HSD17B1
SCHEMBL9921842 0.93 MAOA (0.39) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL9922067 0.93 GRM5 (0.36) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL12919321 0.92 MAOA (0.35) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL9921881 0.92 MAOA (0.35) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL9921803 0.92 MAOA (0.44) KDM4EATML3MBTL1MAOAMAOB
SCHEMBL12919197 0.90 CYP11B2 (0.45) MAOAMAOBACHEMAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2463288-B1 Compound having substituted pyridyl group and pyridoindole ring structure linked through phenylene group, and organic electroluminescent device HODOGAYA CHEMICAL CO LTD (JP) 2014-09-10 EP disclosed
US-8377573-B2 Compound having substituted pyridyl group and pyridoindole ring structure linked through phenylene group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2013-02-19 US disclosed
US-8377573-B2 Compound having substituted pyridyl group and pyridoindole ring structure linked through phenylene group, and organic electroluminescent device HODOGAYA CHEMICAL CO., LTD. (JP) 2013-02-19 US disclosed
EP-2463288-A1 Compound having substituted pyridyl group and pyridoindole ring structure linked through phenylene group, and organic electroluminescent device Hodogaya Chemical Co., Ltd. (JP) 2012-06-13 EP disclosed
US-20110006291-A1 COMPOUND HAVING SUBSTITUTED PYRIDYL GROUP AND PYRIDOINDOLE RING STRUCTURE LINKED THROUGH PHENYLENE GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO. LTD. (JP) 2011-01-13 US disclosed
US-20110006291-A1 COMPOUND HAVING SUBSTITUTED PYRIDYL GROUP AND PYRIDOINDOLE RING STRUCTURE LINKED THROUGH PHENYLENE GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE HODOGAYA CHEMICAL CO. LTD. (JP) 2011-01-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110006291-A1 COMPOUND HAVING SUBSTITUTED PYRIDYL GROUP AND PYRIDOINDOLE RING STRUCTURE LINKED THROUGH PHENYLENE GROUP, AND ORGANIC ELECTROLUMINESCENT DEVICE KCNH3, KCNH2, CHRNA9 KDM4E 572/4885ATM 4185/4885L3MBTL1 791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.